The SUMOylated RNF168 catalyzed by SENP1 prevents the occurrence of LLPS, allowing RNF168 to be recruited to DNA damage sites for nonhomologous DNA end-joining, thereby maintaining genomic stability and even making tumor cells resistant to chemotherapy (36). Here, RNF168 is linked to neoplasm.